Pacira BioSciences, Inc. (PCRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.46B
Last updated: Nov 17, 2026 at 3:04 AM ET
Pacira BioSciences, Inc. (PCRX) P/E Ratio & Valuation History
Pacira BioSciences (PCRX) trades at 20.0x trailing earnings and 2.0x sales. Its P/E of 20.0x is above its 5-year median of 10.9x. Its forward P/E is 9.9x. The median P/E across 11 similar companies is 10.7x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 102.0% higher over the next year. Its free cash flow yield is 11.6%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 20.0x |
| Forward P/E | 9.9x |
| Price to sales | 2.0x |
| Price to book | 2.0x |
| EV/EBITDA | 12.2x |
| Price to FCF | 8.6x |
| EV/FCF | 8.9x |
| PEG | 1.0 |
| FCF yield | 11.6% |
Historical Medians
Against its 10-year medians, its P/E is 1.5% below 20.3x, its P/S is 53.5% below 4.3x and its P/B is 47.4% below 3.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 20.0x | 10.9x | 20.3x |
| P/S | 2.0x | 1.6x | 4.3x |
| P/B | 2.0x | 1.6x | 3.8x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 5.9x in 2024 to 240.3x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $25.88 | 10.9x | 1.6x | 1.6x |
| 2024 | $18.84 | 5.9x | 1.3x | 1.2x |
| 2023 | $33.74 | 11.6x | 2.4x | 2.0x |
| 2022 | $38.61 | 14.9x | 1.3x | 2.3x |
| 2021 | $60.17 | 20.1x | 4.9x | 3.7x |
| 2020 | $59.84 | 27.2x | 6.0x | 4.3x |
| 2019 | $45.30 | 27.1x | 4.5x | 5.3x |
| 2018 | $43.02 | 41.4x | 5.3x | 5.7x |
| 2017 | $45.65 | 240.3x | 6.4x | 6.8x |
| 2016 | $32.30 | 52.1x | 4.4x | 5.5x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PCRX
What is PCRX's forward P/E ratio?
Pacira BioSciences has a forward P/E ratio of 9.9x.
Is PCRX stock overvalued?
GNG's valuation label for PCRX is Fairly valued. Its P/E of 20.0x compares with a median of 10.7x across 11 similar companies.
What is PCRX's price to sales ratio?
Pacira BioSciences has a price to sales ratio of 2.0x.
What is Pacira BioSciences's average P/E ratio over 5 years?
Pacira BioSciences's median P/E over the last 5 years is 10.9x, from 60 month-end values through Oct 2026.
What is PCRX's PEG ratio?
Pacira BioSciences has a PEG ratio of 1.0.
PCRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors